Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic

Background: Cardiovascular diseases(CVD) increase mortality risk from coronavirus infection(COVID-19), but there are concerns that the pandemic has affected supply and demand of acute cardiovascular care. We estimated excess mortality in specific CVDs, both direct, through infection, and indirect, through changes in healthcare. Methods: We used population-based electronic health records from 3,862,012 individuals in England to estimate pre- and post-COVID-19 mortality risk(direct effect) for people with incident and prevalent CVD. We incorporated: (i)pre-COVID-19 risk by age, sex and comorbidities, (ii)estimated population COVID-19 prevalence, and (iii)estimated relative impact of COVID-19 on mortality(relative risk, RR: 1.5, 2.0 and 3.0). For indirect effects, we analysed weekly mortality and emergency department data for England/Wales and monthly hospital data from England(n=2), China(n=5) and Italy(n=1) for CVD referral, diagnosis and treatment until 1 May 2020. Findings: CVD service activity decreased by 60-100% compared with pre-pandemic levels in eight hospitals across China, Italy and England during the pandemic. In China, activity remained below pre-COVID-19 levels for 2-3 months even after easing lockdown, and is still reduced in Italy and England. Mortality data suggest indirect effects on CVD will be delayed rather than contemporaneous(peak RR 1.4). For total CVD(incident and prevalent), at 10% population COVID-19 rate, we estimated direct impact of 31,205 and 62,410 excess deaths in England at RR 1.5 and 2.0 respectively, and indirect effect of 49932 to 99865 excess deaths. Interpretation: Supply and demand for CVD services have dramatically reduced across countries with potential for substantial, but avoidable, excess mortality during and after the COVID-19 pandemic.

[1]  Haniye Sadat Sajadi,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, The Lancet.

[2]  Arturo Gonzalez-Izquierdo,et al.  UK phenomics platform for developing and validating electronic health record phenotypes: CALIBER , 2019, J. Am. Medical Informatics Assoc..

[3]  I. J. Douglas,et al.  OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. , 2020, medRxiv.

[4]  L. Smeeth,et al.  Ethnicity and the first diagnosis of a wide range of cardiovascular diseases: Associations in a linked electronic health record cohort of 1 million patients , 2017, PloS one.

[5]  Scott D. Solomon,et al.  Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic , 2020, Journal of the American College of Cardiology.

[6]  P. Maulik,et al.  Global Alliance for Chronic Disease researchers' statement on multimorbidity. , 2018, The Lancet. Global health.

[7]  Jennifer Jamieson,et al.  Non-Communicable Diseases in Emergencies: A Call to Action , 2013, PLoS currents.

[8]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[9]  Yaolong Chen,et al.  Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines , 2020, Thrombosis and Haemostasis.

[10]  Spiros Denaxas,et al.  Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people , 2015, The Lancet.

[11]  W. Liang,et al.  Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China , 2020, Chest.

[12]  Cardiac patient care during a pandemic: how to reorganise a heart failure unit at the time of COVID-19 , 2020, European journal of preventive cardiology.

[13]  P. Home Cardiovascular outcome trials of glucose-lowering medications: an update , 2019, Diabetologia.

[14]  Spiros Denaxas,et al.  Estimating excess 1- year mortality from COVID-19 according to underlying conditions and age in England: a rapid analysis using NHS health records in 3.8 million adults , 2020, medRxiv.

[15]  Lynnette Brammer,et al.  Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[16]  Amitava Banerjee,et al.  Can the NHS be a learning healthcare system in the age of digital technology? , 2018, BMJ Evidence-Based Medicine.

[17]  S. Bosari,et al.  SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak , 2020, medRxiv.

[18]  F. Fedele,et al.  Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy , 2020, The New England journal of medicine.

[19]  Zhaofeng Chen,et al.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[20]  Rui Ji,et al.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[21]  Scott D. Solomon,et al.  Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic , 2020, Journal of the American College of Cardiology.

[22]  C. Sudlow,et al.  Trends in excess cancer and cardiovascular deaths in Scotland during the COVID-19 pandemic 30 December – 20 April suggest underestimation of COVID-19 related deaths , 2020 .

[23]  R. de Caterina,et al.  Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era , 2020, European heart journal.

[24]  A. Banerjee,et al.  Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency , 2020, medRxiv.

[25]  S. Hagard England , 1995, The Knight and the Blast Furnace.